IRCT2013122811763N15 - Bifidobacterium breve + Bifidobacterium longum + Fructooligosaccharides (FOS) + Lacticaseibacillus casei + Lacticaseibacillus rhamnosus + Lactobacillus acidophilus + Lactobacillus delbrueckii bulgaricus + Streptococcus thermophiles & Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)

Background

Non-alcoholic fatty liver disease is becoming more common, so it's important to focus on different strategies for preventing and managing it (1)

Study overview

It is a randomized, double blind, placebo-controlled clinical trial studying Bifidobacterium breve + Bifidobacterium longum + Fructooligosaccharides (FOS) + Lacticaseibacillus casei + Lacticaseibacillus rhamnosus + Lactobacillus acidophilus + Lactobacillus delbrueckii bulgaricus + Streptococcus thermophiles or placebo in 80 randomized patients with [Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)](brain://0_T4lKylP0CsXkdsY4SiLw/NonAlcoholicFattyLiverDiseaseNafldMetabolic…